January 2017, Volume 3, Issue 1

This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.


Table of Contents

back to top

Columns

  • Marrow-Minded Thursday, December 29th, 2016

    In November’s Editor’s Corner, David Steensma, MD, recounted the “absurdly exotic experience” of eating bone marrow in a café in Milan after speaking about marrow failure at a conference, and walked us through a brief history of the culinary delicacy. We received responses from readers who also appreciated the irony of eating bone marrow as […]

  • Making a Hematology Wishlist, and Checking it Twice Thursday, December 29th, 2016

    Happy New Year! Can you believe it’s 2017 already? Another holiday season passed, another calendar page flipped, another year gone by. I thought that I was pretty good this year, earning a spot on the “nice” list, but Santa still didn’t leave all the presents I wanted under the tree. Here’s a sampling of gifts […]

back to top

Society News

  • Ross Levine, MD Thursday, December 29th, 2016

    In this edition, Ross Levine, MD, talks about his path to medicine, the virtues of debate, and paying mentorship forward. Dr. Levine is the Laurence Joseph Dineen Chair in Leukemia Research and director of the Memorial Sloan Kettering Center for Hematologic Malignancies at Memorial Sloan Kettering Cancer Center in New York, New York. What was […]

  • January 2017: ASH Scholar Award Recipients, Visitor Training Program Open, and more Thursday, December 29th, 2016

    2017 ASH Scholar Award Recipients Announced For more than 30 years, the ASH Scholar Awards have financially supported fellows and junior faculty as they transition from training programs to careers as independent hematology investigators. Each Scholar Award provides up to $100,000 for fellows and $150,000 for junior faculty over a two- to three-year period. The […]

back to top

Features

  • Predatory Publishing: The Dark Side of the Open-Access Movement Thursday, December 29th, 2016

    In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker […]

back to top

Training & Education

  • How long should a patient continue anticoagulation and should she continue during pregnancy? Thursday, December 29th, 2016

    This month, Jean Marie Connors, MD, discusses how long a 31-year-old patient should continue anticoagulation and the recommendations for pregnancy. You Made the Call! We asked, and you answered – See the reader responses below. Also, check out next month’s clinical dilemma! Clinical Dilemma: A 31-year-old female, who had a recent miscarriage at six weeks […]

back to top

Clinical News

  • LYRIC Study: In the Age of Immunomodulatory Therapy, Do We Need New Lymphoma Response Criteria? Thursday, December 29th, 2016

    Since the first internationally accepted response criteria, the Lugano Classification Response Criteria, were published in 1999, advances in immunomodulatory therapies that affect imaging interpretation have resulted in the need for revised criteria for staging and response. To redefine response outcomes with use of immunomodulatory drugs, Bruce D. Cheson, MD, from the Georgetown University Hospital Lombardi […]

  • Examining the Link Between Cirrhosis and Venous Thromboembolism Thursday, December 29th, 2016

    A meta-analysis published in Thrombosis and Haemostasis, by Pasquale Ambrosino, MD, from the Department of Clinical Medicine and Surgery at the Federico II University in Naples, Italy, and authors confirmed the association between cirrhosis and venous thromboembolism (VTE), finding that patients with cirrhosis have a 1.2-percent higher absolute risk of  VTE than patients without cirrhosis […]

  • Overly Restrictive Clinical Trial Exclusion Criteria May Block Patients From Receiving Effective Therapy Thursday, December 29th, 2016

    Many clinical trials exclude patients with comorbidities, active or recent malignancies, organ dysfunction, or poor performance status, meaning that clinical trials typically enroll the “Olympic athletes of patients,” according to clinical trial researchers who spoke with ASH Clinical News about clinical trials’ eligibility criteria in a recent feature article (“Who’s In and Who’s Out?”). Such […]

  • January 2017: NIH’s New Data-Sharing Requirement, New Myeloma Drug Approval, and more Thursday, December 29th, 2016

    FDA Grants Priority Review to Midostaurin for Acute Myeloid Leukemia The U.S. Food and Drug Administration (FDA) granted priority review to midostaurin for adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) or advanced systemic mastocytosis (SM). The decision was based on the results of the phase II RATIFY trial of patients with AML and […]

back to top

On Location

  • Anti-CD19 CAR T-Cell Therapy Has High Response Rate in Refractory, Aggressive Non-Hodgkin Lymphoma Thursday, December 29th, 2016

    For patients with chemo-refractory, aggressive non-Hodgkin lymphoma (NHL), treatment with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (known as KTE-C19) induced a CR rate that was nearly six times higher than what has typically been seen historically, according to results from the phase II ZUMA-1 trial, the first multicenter trial of this immunotherapy-based approach in […]

  • Attempting to Reduce the Chemotherapy Burden of Children With Acute Lymphocytic Leukemia Thursday, December 29th, 2016

    Reduced-intensity treatment was inferior to standard-intensity treatment in duration of disease-free survival (DFS) in pediatric patients with acute lymphocytic leukemia (ALL) who have standard-risk disease and are at a low risk for relapse, according to an analysis of the AIEOP-BFM-ALL 2000 trial. However, reduced-intensity treatment was associated with “dangerous” rates of relapse, according to lead […]

  • Improving Quality of Life Through Gene Therapy for Patients With Hemophilia B Thursday, December 29th, 2016

    Preliminary data from an ongoing phase I/II trial suggest that patients with hemophilia B produced factor IX (FIX) at sufficient levels after receiving a single infusion of an investigational adeno-associated, virus-mediated gene therapy agent. The therapy, called SPK-9001, uses an inactive virus to deliver FIX into a patient’s cells a small section of DNA that, […]

  • Reducing Pain Crises With Novel Selectin Inhibitor in Patients With Sickle Cell Disease Thursday, December 29th, 2016

    Results from the SUSTAIN trial found that the monoclonal antibody crizanlizumab, which targets anti-P-selectin, reduces the frequency of pain crises by nearly half, compared with placebo, in adolescents and adults with sickle cell disease (SCD). These results suggest that crizanlizumab may offer another treatment option for patients with SCD who cannot tolerate or are reluctant […]

back to top